Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.

Trial Details

NCT ID
NCT06922591
Phase
PHASE1 / PHASE2
Sponsor
Tango Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • TNG462
  • RMC-9805
  • RMC-6236
  • mFOLFIRINOX
  • gemcitabine/nab-paclitaxel
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Denver, Colorado, United States|39.73915,-104.9847
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Is ≥18 years of age at the time of signature of the main study ICF.
  • Has an ECOG PS of 0 or 1.
  • Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
  • Arms A and B only: Has a tumor with a RAS mutation

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →